Myeloma

Circulating tumor cells in multiple myeloma serve as a compound biomarker for bone marrow high-risk genomic alterations and tumor load, according to a 2026 study published in Blood by Fokkema and colleagues. This blood-based marker helps clinicians evaluate aggressive disease features without always relying solely on repeated bone marrow biopsies. Genomic Complexity and Circulating Tumor … Read more